OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results (9/11/26)

Opus Genetics Inc. published this content on September 11, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 11, 2026 at 12:49 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]